Antiplatelet and anticoagulation for patients with prosthetic heart valves

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Massel, David R ^a   Little, Stephen H ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; HEMOGLOBIN; PLACEBO;

ANTICOAGULANT THERAPY; ARTERIAL THROMBOEMBOLISM; ATRIAL FIBRILLATION; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GENITAL BLEEDING; HEART VALVE REPLACEMENT; HEMARTHROSIS; HEMOPTYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRAOCULAR HEMORRHAGE; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROPERITONEAL HEMORRHAGE; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; URINARY TRACT HEMORRHAGE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; HEART VALVE PROSTHESIS; META ANALYSIS; METHODOLOGY; ORAL DRUG ADMINISTRATION; CHEMICALLY INDUCED; PROCEDURES;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ASPIRIN; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; HEART VALVE PROSTHESIS; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOEMBOLISM;

EID: 84891640442     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003464.pub2     Document Type: Review

References (57)

1. Altman R, Boullon F, Rouvier J, Raca R, de la Fuente L, Favaloro R. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. Journal of Thoracic and Cardiovascular Surgery 1976;72(1):127-9.
2. Bran M, Capel P, Messin R. Reduction of platelet activity in patients with prosthetic heart valves. Revue Medicate de Bruxelles 1980;1:71-5.
3. Dale J, Myhre E. Prevention of arterial embolism by acetylsalicylic acid and anticoagulants in patients with heart valve prosthesis [Tidsskr nor laegeforen]. Tidsskrift for Den Norske Laegeforening 1976;28:1483-5.
4. Dale J, Myhre E, Storstein O, Stormorken H, Efskind L. Prevention of arterial thromboembolism with acetylsalicylic acid: a controlled clinical study in patients with aortic ball valves. American Heart Journal 1977;94:101-11.
5. Dong MF, Ma ZS, Ma SJ, Chai SD, Tang PZ, Yao DK, et al. Anticoagulation therapy with combined low dose aspirin and warfarin following mechanical heart valve replacement. Thrombosis Research 2011;128:e91-4.
6. Kasahara T. Clinical effect of dipyridamole ingestion after prosthetic heart valve replacement: especially on the blood coagulation system. Japanese Association of Thoracic Surgery 1977;25:1007-21.
7. Laffort P, Roudaut R, Rogues X, Lafitte S, Deville C, Bonnet J, et al. Early and long-term (one year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis. Journal of the American College of Cardiology 2000;35(3):739-46.
8. Pengo V, Palareti G, Cucchini U, Molinatti M, Del Bono R, Baudo F, et al. Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP). Clinical and Applied Thrombosis Hemostasis 2007;13(3):241-8.
9. Meschengieser S, Fondevila C, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. Journal of Thoracic Cardiovascular Surgery 1997;113:910-6.
10. Groupe de Researche P.A.C.T.E. Prevention of systemic thromboembolic accidents in patients with prosthetic valves [Prevention des accidents thromboemboliques systemiques chez les porteurs de prostheses valvulaires artificielles: essai cooperatif du dipyridamole]. Coeur 1978;9:915-69.
11. Rajah S, Sreeharan N, Joseph A. A prospective trial of dipyridamole and warfarin in heart valve patients (abstract). Acta Therapeutica 1980;6 Suppl 93:54.
12. Farah E, Cadhilac M, Boubaker C, Starkman C, Acar J. Thromboembolic risk in prosthetic valve carriers. Prevention trial. Scandinavian Journal of Haematology. Supplementum 1981;38:97-119.
13. Starkman C, Estampes B, Vernant P, Acar J. Prevention of systemic thromboembolic accidents in patients with prosthetic valves: a prospective study of anti-vitamin K - dipyridamole [Prevention des accidents thromboemboliques systemiques chez les patients porteurs de prostheses valvulaires artificielles: essai prospectif de l'assocation antivitamines K-dipyridamole]. Archives des Maladies du Couer et des Vaisseaux 1982;75:85-8.
14. Arai T. Effect of dipyridamole on arterial thrombosis development rate after replacement with the artificial valve. Japanese Journal of Thoracic Surgery 1971;24(8):601.
15. Sullivan J, Harken D, Gorlin R. Effect of dipyridamole on the incidence of arterial emboli after cardiac valve replacement. Circulation 1969;39(5 Suppl 1):149-53.
16. Sullivan J, Harken D, Gorlin R. Pharmacologic control of thromboembolic complications in patients with substitute heart valves. New England Journal of Medicine 1971;284:1391-4.
17. Turpie A, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, et al. A comparison of aspirin with placebo in patients with warfarin after heart-valve replacement. New England Journal of Medicine 1993;329:524-9.
18. Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. American Journal of Cardiology 1983;51:1537-41.
19. Hassouna A, Allam H, Awad A, Hassaballah F. Standard versus low-level anticoagulation combined to low-dose dipyridamole after mitral valve replacement. Cardiovascular Surgery 2000;8(6):491-8.
20. Hayashi J, Nakazawa S, Oguma F, Miyamura H, Eguchi S. Combined warfarin and antiplatelet therapy after St. Jude medical valve replacement for mitral valve disease. Journal of the American College of Cardiology 1994;23:672-7.
21. Moriyama Y, Nakamura K, Kariyazono H, Toyohira H, Taira A. Influence of low-intensity anticoagulation and low-dose antiplatelet agent on coagulation-fibrinolysis system after mechanical prosthetic valve replacement. Journal of Thoracic Cardiovascular Surgery 1998;115:952-4.
22. Saitoh H, Matsumoto H, Yagyu, K, Miyawaki F, Ide H, Furuse A. Thromboembolism and antithrombogenic therapy after prosthetic valve replacement. Japanese Journal of Thoracic Surgery 1998;41(2):97-102.
23. Toyohira H, Nakamura K, Kariyazono H, Yamada K, Moriyama Y, Shimokawa S, et al. Significance of combined use of anticoagulants and antiplatelet agents in the early stage after prosthetic valve replacement. Japanese Journal of Thoracic Surgery 1995;48(9):749-55.
24. Voith L, Pfliegler G, Hegedus I, Medgyesi F, Bodi A, Csapo K, et al. Coumarin combined with low-dose acetylsalicylic acid in the prevention of thromboembolic complications in patients with mitral and aortic valve prosthesis [Kumarin es kis adagu acetilszalicilsav egyuttes adasa mitralis es aorta mechanikus mubillentyus betegek thromboembolias szovodmenyeinek megelozeseben]. Orvosi Hetilap 1997;138(15):925-9.
25. Altman R, Rouvier J, Gurfinkel E, D'Ortencio O, Manzanel R, de La Fuente L, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. Journal of Thoracic and Cardiovascular Surgery 1991;101:427-31.
26. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
27. Berlin J, University of Pennsylvania Meta-analysis Blinding Study Group. Does blinding readers affect the results of meta-analysis?. Lancet 1997;350:185-6.
28. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635-41.
29. College of American Pathologists Coagulation Survey Set. CG2-C. Northfield IL: College of American Pathologists 1997.
30. Cappelleri JC, Fiore LD, Brophy, Deykin D, Lau J. Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: a metaanalysis. American Heart Journal 1995;130:547-52.
31. Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. Journal of the American College of Cardiology 1986;8(6 Suppl B):41B-56B.
32. Clarke M, Stewart L. Obtaining data from randomized controlled trials: how much do we need for reliable and informative meta-analyses?. In: Chalmers I, Altman D editor(s). Systematic Reviews. London: BMJ, 1995:37-47.
33. Cook D, Guyatt G, Ryan G, Clifton J, Buckingham L, Willan A, et al. Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA 1993;269:2749-53.
34. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91.
35. Eikelboom JW, Hart RG. Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. American Journal of Hematology 2012;87(Suppl 1):S100-7.
36. Fiore L, Brophy M, Deykin D, et al. The efficacy and safety of the addition of aspirin in patients with oral anticoagulants after heart valve replacement. Blood 1993;82(Suppl):409A.
37. Fleiss J. Statistical Methods for Rates and Proportions. 2nd Edition. New York: J Whiley, 1981.
38. Hermans H, Vanassche T, Herijgers P, Meuris B, Herregods MC, Van de Werf F, et al. Antithrombotic therapy in patients with heart valve prostheses. Cardiology in Review 2013;21(1):27-36.
39. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
40. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8S-21S.
41. Hoffman R, Brenner B. The promise of novel direct oral anticoagulants. Best Practice & Research. Clinical Haematology 2012;25(3):351-60.
42. Lau J, Ioannidis J, Schmid C. Quantitative synthesis in systematic review. Annals of Internal Medicine 1997;127:820-6.
43. Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomised controlled trials in EMBASE. 4th International Cochrane Colloquium 20-24 Oct 1996, Adelaide, Australia 1996.
44. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2011.
45. Loewen P, Sunderji R, Gin K. The efficacy and safety of combination warfarin and ASA therapy: a systemic review of the literature and update of guidelines. Canadian Journal of Cardiology 1998;14:717-26.
46. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
47. Patrano C, Coller B, Dalen JE, Fitzgerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationship among dose, effectiveness, and side effects. Chest 2001;119(1 Suppl):39S-63S.
48. Pouleur J, Buyse M. Effects of dipyridamole in combination with anticoagulant therapy on survival and thromboembolic events in patients with prosthetic heart valves. A meta-analysis of the randomized trials. Journal of Thoracic Cardiovascular Surgery 1995;110:463-72.
49. Ray JG, Turpie AG. Survey of cardiac surgeons' perceptions of the addition of ASA to warfarin for patients with mechanical heart valves. Canadian Journal of Cardiology 1997;13:1162-5.
50. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
51. Schultz K, Chalmers I, Hayes R, Altman D. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
52. Stein P, Alpert J, Bussey H, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119 (1 Suppl):220S-7S.
53. Sudlow CLM, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD001246.pub2]
54. Aramendia JI, Mestresb C-A, Martinez-Leónc J, Camposd V, Muñoze G, Navase C. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (TRAC): prospective, randomized, co-operative trial. European Journal of Cardiothoracic Surgery 2005;27:854-60.
55. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373(9665):723-31.
56. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine 2009;361(11):1045-57.
57. Massel D, Little S. Risks and benefits of adding antiplatelet therapy to warfarin among patients with prosthetic heart valves. Journal of the American College of Cardiology 2001;37(2):569-78.